Autoimmune kidney diseases are a group of conditions in which the body’s immune system mistakenly attacks the kidneys, most often the glomeruli, the tiny filtering units where blood is cleaned. They range from relatively common conditions like IgA nephropathy and lupus nephritis to rare emergencies like anti-glomerular basement membrane disease. Though the triggers and mechanisms differ, most share a core problem: immune proteins depositing in or attacking kidney tissue, setting off inflammation that can quietly erode kidney function or, in some cases, destroy it within weeks.
How the Immune System Damages the Kidneys
Most autoimmune kidney diseases involve one of two basic processes, and sometimes both at once. In the first, the immune system forms clumps of antibodies and their targets (immune complexes) that circulate through the bloodstream and get trapped in the glomeruli. Once lodged there, they trigger inflammation. These trapped complexes can also form directly within the kidney itself when antibodies bind to proteins already sitting on or near the glomerular structures.1PubMed. Mechanisms of immune-deposit formation and the mediation of immune renal injury In the second process, antibodies target specific components of the kidney directly, as in anti-GBM disease, where antibodies attack a particular protein in the basement membrane that supports the filtering barrier.
Once immune deposits form, the complement system, a cascade of blood proteins that amplifies inflammation, kicks in. Research comparing complement activation across several autoimmune kidney diseases has found that both the classical and alternative complement pathways contribute to glomerular damage, and both represent potential therapeutic targets.2PubMed Central. Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis In diseases like C3 glomerulopathy and some forms of membranoproliferative glomerulonephritis, the alternative complement pathway is overactive on its own, sometimes because autoantibodies stabilize the enzymes that drive it, making it chew through kidney tissue faster than it should.3PubMed. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy
The Major Types
Autoimmune kidney diseases are often grouped by which part of the glomerulus is targeted, what kind of immune deposits show up on biopsy, and which antibodies drive the damage. Here are the most important ones.
Lupus Nephritis
Lupus nephritis is one of the most serious complications of systemic lupus erythematosus (SLE). It occurs when immune complexes containing anti-DNA antibodies deposit in the glomeruli, triggering inflammation. The disease is classified into several classes (I through VI) based on the pattern and severity of glomerular injury seen on biopsy. A revised international classification updated in 2018 refined the definitions of key lesions, eliminated some older subdivisions, and introduced activity and chronicity scoring to better predict outcomes.4PubMed. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis
Within lupus nephritis, not all patterns carry the same risk. A study comparing “pure” lupus membranous nephritis (affecting just the outer layer of the glomerular capillary wall) with “mixed” forms that combine membranous and proliferative features found that while both groups achieved similar response rates and kidney survival over time, patients with the pure membranous form actually had worse overall survival when kidney failure and death were considered together.5PubMed Central. Long-term kidney and patient outcomes in pure versus mixed lupus membranous nephritis That finding underscores why biopsy classification matters: it can change treatment intensity and monitoring.
IgA Nephropathy
IgA nephropathy is the most common primary glomerular disease worldwide. It develops when abnormal forms of the antibody IgA1 build up in the blood and deposit in the glomerular mesangium, the supportive tissue between capillary loops. The leading explanation is a “multi-hit” process: the patient produces IgA1 molecules with incomplete sugar chains (galactose-deficient IgA1), the immune system then creates autoantibodies that recognize these abnormal molecules, those antibodies and the deficient IgA1 form immune complexes, and the complexes lodge in the kidneys and provoke inflammation.6PubMed Central. Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment7Clinical Kidney Journal. Immune abnormalities in IgA nephropathy
This multi-hit model has been foundational, but newer research suggests it may be too linear. Recent reviews note that IgA nephropathy has a recurrent, self-amplifying character that a simple stepwise model does not fully capture.8PubMed Central. Immunoglobulin A Nephropathy: Molecular Pathogenesis and Targeted Therapy Still, the model has driven the development of targeted therapies now entering clinical practice.
Membranous Nephropathy
In primary membranous nephropathy, autoantibodies target proteins on podocytes, the specialized cells that wrap around glomerular capillaries and help maintain the filtration barrier. The dominant target in most cases is a protein called PLA2R (phospholipase A2 receptor): autoantibodies against it are found in roughly 70 to 80 percent of patients with primary membranous nephropathy.9PubMed Central. The Role of Anti-PLAR and Anti-THSD7A Antibodies in the Pathogenesis and Diagnostics of Primary Membranous Nephropathy A second target, a protein called THSD7A, accounts for a small additional fraction, roughly 2 to 5 percent.10PubMed Central. Autoantigens PLA2R and THSD7A in membranous nephropathy share a common epitope motif in the N-terminal domain
The discovery of these anti-podocyte antibodies transformed how membranous nephropathy is managed. Serum levels of anti-PLA2R can now be used to diagnose primary membranous nephropathy without a biopsy in some cases, to distinguish it from secondary forms caused by infections or cancers, and to track how well treatment is working.11PubMed Central. Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy
Anti-GBM Disease
Anti-glomerular basement membrane (anti-GBM) disease is rare but dramatic. Autoantibodies attack specific regions of type IV collagen in the basement membrane that supports the glomerular capillary wall. When the lungs are also affected (the same collagen sits in the lung’s air sacs), the condition is called Goodpasture syndrome, and patients can present with both kidney failure and coughing up blood. This combination of diffuse lung bleeding and glomerulonephritis is known as pulmonary-renal syndrome, which can rapidly progress to respiratory failure and end-stage kidney disease if not treated urgently.12Breathe. Pulmonary renal syndrome: a clinical review
ANCA-Associated Vasculitis
In ANCA-associated vasculitis (AAV), autoantibodies target proteins inside white blood cells, mainly myeloperoxidase (MPO) or proteinase 3 (PR3). These antibodies activate neutrophils, which then attack the walls of small blood vessels throughout the body, including those in the kidneys. Kidney involvement typically shows up on biopsy as a “pauci-immune” glomerulonephritis, meaning there is severe inflammation and often crescent formation but very little immune complex deposition compared with lupus or IgA nephropathy.
AAV can be aggressive. In a study of patients with PR3-ANCA vasculitis and kidney involvement, about 29 percent were dependent on dialysis at the time of diagnosis, and 20 percent died within a year. Being older than 65 or needing dialysis at diagnosis were both strong risk factors for early death.13PubMed Central. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement AAV is also one of the most common causes of pulmonary-renal syndrome alongside anti-GBM disease.14PubMed Central. Microscopic polyangiitis with pulmonary involvement: Case Report
C3 Glomerulopathy
C3 glomerulopathy (C3G) is ultra-rare and driven by unchecked activation of the alternative complement pathway. Rather than the usual pattern of antibody-mediated damage, the hallmark here is massive deposition of the complement protein C3 in glomeruli with little or no antibody staining on biopsy.15PubMed Central. C3 glomerulopathy: a kidney disease mediated by alternative pathway deregulation In autoimmune forms, the patient produces antibodies that stabilize or overstimulate key complement enzymes, effectively leaving the complement system’s brakes off. C3G occurs in both children and adults, and the disease can be difficult to manage because standard immunosuppression does not always rein in complement overactivity.16Kidney Medicine. C3 Glomerulopathy Diagnosis, Current Treatments, and Emerging Therapies
Warning Signs and Clinical Patterns
Autoimmune kidney diseases often announce themselves through two recognizable clinical patterns, each reflecting a different kind of glomerular injury.
The nephrotic pattern is dominated by heavy protein loss in the urine (more than 3 grams per day), low blood albumin, and noticeable swelling, usually in the legs, ankles, and around the eyes. High cholesterol and an increased risk of blood clots often accompany it.17PubMed Central. Clinical presentation & management of glomerular diseases: hematuria, nephritic & nephrotic syndrome Membranous nephropathy is a classic cause of nephrotic syndrome. IgA nephropathy can cause it too, though less commonly.
The nephritic pattern looks different. It tends to feature blood in the urine (often visible to the naked eye), rising blood pressure, declining kidney function, and moderate rather than massive protein loss. Nephritic presentations carry a worse prognosis on average and are typical of conditions like ANCA-associated vasculitis, anti-GBM disease, and the proliferative classes of lupus nephritis.17PubMed Central. Clinical presentation & management of glomerular diseases: hematuria, nephritic & nephrotic syndrome Patients with a nephritic presentation tend to have significantly lower kidney filtration rates compared to those with a nephrotic presentation, and blood in the urine is far more frequent.18PubMed. Changes in renal microcirculation in patients with nephrotic and nephritic syndrome: The role of resistive index
Some patients fall outside these neat categories. When autoimmune kidney disease attacks both the lungs and the kidneys at once, the result is pulmonary-renal syndrome, characterized by coughing up blood (from small vessel bleeding in the lungs) alongside rapidly worsening kidney function. ANCA-associated vasculitis and anti-GBM disease are the two most common culprits. This presentation is a medical emergency: without rapid treatment, patients can progress to respiratory failure and permanent kidney loss within days.12Breathe. Pulmonary renal syndrome: a clinical review
Many autoimmune kidney diseases also begin with subtle or nonspecific symptoms. Fatigue, foamy urine (from protein), mild ankle swelling, or a slight rise in blood pressure may be the only clues for months. By the time symptoms become obvious, significant kidney damage may already have occurred, which is why routine blood and urine tests matter for anyone with a known autoimmune condition.
From Urine Test to Kidney Biopsy
Diagnosis typically moves from simple screening tests to increasingly specialized investigations, guided by what the early findings suggest.
The first clue often comes from a basic urine test. Protein and blood in the urine together are a strong signal that something is wrong with the glomeruli. Automated analyzers can now measure the shape of red blood cells in urine, distinguishing “dysmorphic” cells that have been distorted by squeezing through damaged glomeruli from normal-shaped cells that come from bleeding elsewhere in the urinary tract. One study found that using a urinary red cell distribution threshold of about 20 percent dysmorphic cells achieved high sensitivity for identifying glomerular hematuria.19PubMed Central. Diagnostic Characteristics of Urinary Red Blood Cell Distribution Incorporated in UF-5000 for Differentiation of Glomerular and Non-Glomerular Hematuria However, the combination of significant hematuria and proteinuria on a standard urinalysis performs nearly as well as formal dysmorphic red cell analysis for predicting glomerulonephritis.20Nephrology Dialysis Transplantation. Urinalysis for the diagnosis of glomerulonephritis: role of dysmorphic red blood cells
Blood tests add important pieces. Kidney filtration rate, albumin, and markers like cystatin C help quantify how much function has been lost. Crucially, autoantibody levels are often affected alongside kidney markers: research shows that markers like estimated filtration rate, cystatin C, and albumin are all significantly altered in patients who have circulating autoantibodies, and those with the worst kidney function tend to have higher autoantibody levels.21PubMed Central. Evaluation of renal markers in systemic autoimmune diseases Specific autoantibody tests can narrow the diagnosis further: anti-PLA2R antibodies point toward primary membranous nephropathy, ANCA (MPO or PR3) suggests vasculitis, anti-GBM antibodies indicate anti-GBM disease, and complement levels help distinguish conditions driven by complement overactivation.
The kidney biopsy remains the diagnostic gold standard for most autoimmune kidney diseases. Tissue is examined under three different methods. Light microscopy reveals the overall pattern of injury, such as crescent formation, scarring, or thickening of the capillary walls. Immunofluorescence shows which immune proteins (IgG, IgA, IgM, complement components) are deposited and where. And electron microscopy provides ultrastructural detail that the other two methods cannot match, such as the precise location and shape of immune deposits.22PubMed Central. Electron Microscopy in Renal Biopsy Interpretation: When and Why It Still Matters All three together are often needed to reach a definitive diagnosis, because different autoimmune kidney diseases can look similar on one method but are clearly distinguishable on another.
Emerging Biomarkers and Reducing the Need for Biopsy
A biopsy is invasive, carries a small risk of bleeding, and can only sample a tiny piece of the kidney. Researchers are actively looking for alternatives. In lupus nephritis, urinary biomarkers like monocyte chemoattractant protein-1 (MCP-1) have been correlated with histological findings and may help detect disease flares before traditional blood and urine markers change.23PubMed Central. Urinary biomarkers in lupus nephritis More recently, urinary exosomes, tiny vesicles shed by kidney cells, have emerged as a potential source of molecular information. These exosomes contain stable fragments of RNA and proteins that may reflect what is happening inside the kidney in real time, offering a possible non-invasive window into disease activity, treatment response, and prognosis.24PubMed Central. Urinary Exosomes as Potential Biomarkers for Diagnosis, Disease Activity Assessment, Treatment Monitoring, and Prognosis in Lupus Nephritis
For membranous nephropathy specifically, the discovery of anti-PLA2R antibodies has already shifted practice. In a patient with nephrotic syndrome and high anti-PLA2R levels, many nephrologists are now comfortable diagnosing primary membranous nephropathy and starting treatment without a biopsy, reserving tissue sampling for cases where the antibody test is negative or the clinical picture is atypical.11PubMed Central. Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy This kind of antibody-guided management may expand to other autoimmune kidney diseases as new targets are identified.
Genetic Susceptibility
Autoimmune kidney diseases are not simply inherited, but genes clearly influence who is vulnerable. The strongest genetic signals come from the HLA region, a stretch of DNA that encodes the proteins your immune system uses to present fragments of invaders (and, in autoimmune disease, fragments of your own tissues) to T cells. Polymorphisms in HLA class II genes, especially in the region of HLA-DRB1, are associated with increased risk for several autoimmune kidney diseases.25PubMed Central. Deciphering the Genetic Code of Autoimmune Kidney Diseases
Anti-GBM disease offers a particularly clear example. Up to 80 percent of patients carry an HLA-DR2 haplotype. Detailed analysis has mapped out a hierarchy of risk at the DRB1 locus: certain alleles (DRB1*15, DRB1*04) increase susceptibility, while others (DRB1*07) are protective. The most likely explanation is that the risk-associated HLA molecules are especially good at presenting fragments of the target collagen protein to T cells, initiating the autoimmune attack.26PubMed. Susceptibility to anti-glomerular basement membrane disease is strongly associated with HLA-DRB1 genes Beyond HLA, genes involved in inflammatory signaling pathways and antibody receptors on immune cells also contribute to risk across multiple autoimmune kidney diseases.25PubMed Central. Deciphering the Genetic Code of Autoimmune Kidney Diseases
For the average patient, knowing about genetic risk mostly matters in two ways. First, having a first-degree relative with an autoimmune disease modestly raises your own risk, which may justify earlier screening if you develop suspicious symptoms. Second, as genetic testing becomes more accessible, certain HLA profiles might eventually help predict which patients will respond to particular treatments, though clinical practice has not yet reached that point for most autoimmune kidney diseases.
Conditions That Mimic Autoimmune Kidney Disease
Not every glomerulonephritis that looks autoimmune on first glance truly is. Several conditions can produce confusingly similar biopsy patterns and clinical presentations, and mistaking one for another can lead to the wrong treatment.
One important mimic is IgA-dominant post-infectious glomerulonephritis (IgA-PIGN). This develops after a bacterial infection, particularly staphylococcal infections, and shows prominent IgA deposits on biopsy, which can look very much like IgA nephropathy. However, the two conditions have different causes and different treatments. IgA-PIGN requires antibiotics and sometimes steroids, while IgA nephropathy is a chronic autoimmune condition managed with long-term immunosuppression. Distinguishing them relies on clinical context (recent infection, low complement levels, acute onset) and biopsy details such as the presence of characteristic “hump-like” deposits under the electron microscope.27PubMed Central. A rare case of Immunoglobulin A dominant post-infectious glomerulonephritis (IgA PIGN) in a young patient A comparative study found that IgA-PIGN universally shows diffuse endocapillary hypercellularity and subepithelial hump deposits, features essentially absent in IgA nephropathy, and that low complement C3 levels, acute kidney injury, and low serum albumin serve as useful non-invasive clues to tell them apart.28PubMed Central. A comparative study on the clinicopathological features and short-term prognosis of IgA-dominant infection-related glomerulonephritis and IgA nephropathy
Another increasingly recognized mimic is kidney injury caused by immune checkpoint inhibitor (ICI) cancer drugs. These medications, which work by unleashing the immune system against tumors, can sometimes unleash it against the kidneys as well. Among patients who developed acute kidney injury on checkpoint inhibitors and underwent biopsy, the most common finding was acute tubulointerstitial nephritis (inflammation of the kidney’s tubules and surrounding tissue) in roughly 83 percent of cases.29Journal for ImmunoTherapy of Cancer. Acute kidney injury in patients treated with immune checkpoint inhibitors This is not a classic autoimmune glomerulonephritis, but it is immune-mediated and can be confused with autoimmune kidney disease, especially when it occurs in patients who already have an autoimmune condition. Recognizing it matters because the treatment (usually stopping the checkpoint inhibitor and giving corticosteroids) differs from that for primary autoimmune glomerulonephritis.
Monoclonal gammopathies of renal significance, where an abnormal clone of immune cells produces a protein that damages the kidneys, can also mimic autoimmune glomerulonephritis on light microscopy. Sorting these out may require specialized immunofluorescence staining for specific antibody subtypes, immunoelectron microscopy, or even proteomic analysis of the tissue deposits.30PubMed Central. Diagnostic and Therapeutic Aspects of Monoclonal Gammopathies of Renal Significance (MGRS): An Update The stakes of getting the diagnosis right are high: treating a monoclonal gammopathy with the immunosuppression used for lupus nephritis would miss the underlying clone entirely, while treating an autoimmune disease with chemotherapy aimed at a clone that does not exist would be both toxic and futile.